TY - JOUR
T1 - The ER membrane-anchored ubiquitin ligase Hrd1 is a positive regulator of T-cell immunity
AU - Xu, Yuanming
AU - Zhao, Fang
AU - Qiu, Quan
AU - Chen, Kun
AU - Wei, Juncheng
AU - Kong, Qingfei
AU - Gao, Beixue
AU - Melo-Cardenas, Johanna
AU - Zhang, Bin
AU - Zhang, Jinping
AU - Song, Jianxun
AU - Zhang, Donna D.
AU - Zhang, Jianing
AU - Fan, Yunping
AU - Li, Huabin
AU - Fang, Deyu
N1 - Funding Information:
We thank Fang lab members for critical reading of the manuscript and constructive suggestions during our research. This work was supported by National Institutes of Health R01 grants (AI079056, AI108634 and AR006634) to D.F. and by National Natural Science Grants and Shanghai Committee of Science and Technology Grant (no. 14DZ2260300) to H.L. (nos 81271054 and 81470673) to H.L.
PY - 2016/7/15
Y1 - 2016/7/15
N2 - Identification of positive regulators of T-cell immunity induced during autoimmune diseases is critical for developing novel therapies. The endoplasmic reticulum resident ubiquitin ligase Hrd1 has recently emerged as a critical regulator of dendritic cell antigen presentation, but its role in T-cell immunity is unknown. Here we show that genetic deletion of Hrd1 in mice inhibits T-cell proliferation, production of IL-2, and differentiation of Th1 and Th17 cells, and consequently protects mice from experimental autoimmune encephalomyelitis. Hrd1 facilitates T-cell proliferation by the destruction of cyclin-dependent kinase inhibitor p27 kip1, and deletion of p27 kip1 in Hrd1-null T-cells rescues proliferative capacity but not the production of cytokines, including IL-2, IFN-3 and IL-17. T-cell expression of Hrd1 is higher in patients with multiple sclerosis than in healthy individuals, and knockdown of Hrd1 in human CD4 + T cells inhibits activation and differentiation to Th1 and Th17 cells. Our study identifies Hrd1 as a previously unappreciated positive regulator of T cells and implies that Hrd1 is a potential therapeutic target for autoimmune diseases.
AB - Identification of positive regulators of T-cell immunity induced during autoimmune diseases is critical for developing novel therapies. The endoplasmic reticulum resident ubiquitin ligase Hrd1 has recently emerged as a critical regulator of dendritic cell antigen presentation, but its role in T-cell immunity is unknown. Here we show that genetic deletion of Hrd1 in mice inhibits T-cell proliferation, production of IL-2, and differentiation of Th1 and Th17 cells, and consequently protects mice from experimental autoimmune encephalomyelitis. Hrd1 facilitates T-cell proliferation by the destruction of cyclin-dependent kinase inhibitor p27 kip1, and deletion of p27 kip1 in Hrd1-null T-cells rescues proliferative capacity but not the production of cytokines, including IL-2, IFN-3 and IL-17. T-cell expression of Hrd1 is higher in patients with multiple sclerosis than in healthy individuals, and knockdown of Hrd1 in human CD4 + T cells inhibits activation and differentiation to Th1 and Th17 cells. Our study identifies Hrd1 as a previously unappreciated positive regulator of T cells and implies that Hrd1 is a potential therapeutic target for autoimmune diseases.
UR - http://www.scopus.com/inward/record.url?scp=84978760294&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84978760294&partnerID=8YFLogxK
U2 - 10.1038/ncomms12073
DO - 10.1038/ncomms12073
M3 - Article
C2 - 27417417
AN - SCOPUS:84978760294
SN - 2041-1723
VL - 7
JO - Nature communications
JF - Nature communications
M1 - 12073
ER -